{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:50:50Z","timestamp":1754164250419,"version":"3.41.2"},"reference-count":96,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.gtc.2025.02.007","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T17:31:16Z","timestamp":1744133476000},"page":"569-587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["New Pharmacologic Treatments in Pediatric Neurogastroenterology"],"prefix":"10.1016","volume":"54","author":[{"given":"Alex","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin C.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gtc.2025.02.007_bib1","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8024171","article-title":"The enteric nervous system and its emerging role as a therapeutic target","volume":"2020","author":"Fleming","year":"2020","journal-title":"Gastroenterol Res Pract"},{"issue":"6","key":"10.1016\/j.gtc.2025.02.007_bib2","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1053\/j.gastro.2016.02.015","article-title":"Functional disorders: children and adolescents","volume":"150","author":"Hyams","year":"2016","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.gtc.2025.02.007_bib3","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1053\/j.gastro.2016.03.035","article-title":"Rome IV-functional GI disorders: disorders of gut-brain interaction","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.gtc.2025.02.007_bib4","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/MPG.0b013e31818936d1","article-title":"Functional abdominal pain: time to get together and move forward","volume":"47","author":"Nurko","year":"2008","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gtc.2025.02.007_bib5","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.02.027","article-title":"Biopsychosocial aspects of functional gastrointestinal disorders","author":"Van Oudenhove","year":"2016","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.gtc.2025.02.007_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjpo-2023-002166","article-title":"ESPGHAN and NASPGHAN 2023 protocol for paediatric FAPD treatment guidelines (standard operating procedure)","volume":"7","author":"Gordon","year":"2023","journal-title":"BMJ Paediatr Open"},{"issue":"2","key":"10.1016\/j.gtc.2025.02.007_bib7","first-page":"140","article-title":"Pediatric gastrointestinal motility disorders: challenges and a clinical update","volume":"4","author":"Chumpitazi","year":"2008","journal-title":"Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.gtc.2025.02.007_bib8","first-page":"16","article-title":"Gastrointestinal motility disorders in children","volume":"10","author":"Ambartsumyan","year":"2014","journal-title":"Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.gtc.2025.02.007_bib9","first-page":"12","article-title":"The latest FDA approvals for children\u2019s medications","volume":"40","author":"Shah","year":"2023","journal-title":"Contemp Pediatr"},{"issue":"3","key":"10.1016\/j.gtc.2025.02.007_bib10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40272-023-00563-0","article-title":"An update of pharmacological management in children with functional constipation","volume":"25","author":"de Geus","year":"2023","journal-title":"Paediatr Drugs"},{"issue":"1","key":"10.1016\/j.gtc.2025.02.007_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14309\/ajg.0000000000001036","article-title":"ACG clinical guideline: management of irritable bowel syndrome","volume":"116","author":"Lacy","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.gtc.2025.02.007_bib12","first-page":"154","article-title":"Linaclotide (Linzess) for irritable bowel syndrome with constipation and for chronic idiopathic constipation","volume":"38","author":"Thomas","year":"2013","journal-title":"P T"},{"issue":"4","key":"10.1016\/j.gtc.2025.02.007_bib13","first-page":"207","article-title":"Plecanatide (Trulance) for chronic idiopathic constipation and irritable bowel syndrome with constipation","volume":"43","author":"Kamuda","year":"2018","journal-title":"P T"},{"issue":"1","key":"10.1016\/j.gtc.2025.02.007_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/2050640612474446","article-title":"Linaclotide: a new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation","volume":"1","author":"Corsetti","year":"2013","journal-title":"United European Gastroenterol J"},{"issue":"3","key":"10.1016\/j.gtc.2025.02.007_bib15","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S2468-1253(23)00398-9","article-title":"Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"9","author":"Di Lorenzo","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.gtc.2025.02.007_bib16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/ajg.2017.495","article-title":"Efficacy and tolerability of guanylate cyclase-c agonists for irritable bowel syndrome with constipation and chronic idiopathic constipation: a systematic review and meta-analysis","volume":"113","author":"Shah","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.gtc.2025.02.007_bib17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40272-021-00444-4","article-title":"The use of linaclotide in children with functional constipation or irritable bowel syndrome: a retrospective chart review","volume":"23","author":"Baaleman","year":"2021","journal-title":"Paediatr Drugs"},{"issue":"3","key":"10.1016\/j.gtc.2025.02.007_bib18","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/jpn3.12306","article-title":"Safety and efficacy of linaclotide in children aged 2-5 years with functional constipation: phase 2, randomized study","volume":"79","author":"Di Lorenzo","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"10.1016\/j.gtc.2025.02.007_bib19","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2147\/CIA.S2938","article-title":"Lubiprostone: a novel treatment for chronic constipation","volume":"3","author":"Lacy","year":"2008","journal-title":"Clin Interv Aging"},{"issue":"2","key":"10.1016\/j.gtc.2025.02.007_bib20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/2040622314567678","article-title":"Lubiprostone in constipation: clinical evidence and place in therapy","volume":"6","author":"Wilson","year":"2015","journal-title":"Ther Adv Chronic Dis"},{"issue":"3","key":"10.1016\/j.gtc.2025.02.007_bib21","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.cgh.2021.04.005","article-title":"Lubiprostone for pediatric functional constipation: randomized, controlled, double-blind study with long-term extension","volume":"20","author":"Benninga","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.gtc.2025.02.007_bib22","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/MPG.0000000000003280","article-title":"Safety of lubiprostone in pediatric patients with functional constipation: a nonrandomized, open-label trial","volume":"73","author":"Hussain","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"10.1016\/j.gtc.2025.02.007_bib23","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/MPG.0000000000000176","article-title":"Lubiprostone for the treatment of functional constipation in children","volume":"58","author":"Hyman","year":"2014","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gtc.2025.02.007_bib24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/164_2016_103","article-title":"Serotonergic mechanisms regulating the gi tract: experimental evidence and therapeutic relevance","volume":"239","author":"Terry","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.gtc.2025.02.007_bib25","first-page":"49","article-title":"Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation","volume":"3","author":"Wong","year":"2010","journal-title":"Clin Exp Gastroenterol"},{"issue":"4","key":"10.1016\/j.gtc.2025.02.007_bib26","article-title":"Cisapride treatment for gastro-oesophageal reflux in children","volume":"2010","author":"Maclennan","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.gtc.2025.02.007_bib27","first-page":"1269","article-title":"Lessons from cisapride","volume":"164","year":"2001","journal-title":"CMAJ (Can Med Assoc J)"},{"issue":"10","key":"10.1016\/j.gtc.2025.02.007_bib28","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.cgh.2022.01.024","article-title":"Tegaserod: what's old is new again","volume":"20","author":"Sayuk","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.gtc.2025.02.007_bib29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1756283X11423706","article-title":"Prucalopride: safety, efficacy and potential applications","volume":"5","author":"Quigley","year":"2012","journal-title":"Therap Adv Gastroenterol"},{"issue":"10","key":"10.1016\/j.gtc.2025.02.007_bib30","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s40264-019-00835-0","article-title":"Cardiovascular safety of prucalopride in patients with chronic constipation: a multinational population-based cohort study","volume":"42","author":"Gilsenan","year":"2019","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.gtc.2025.02.007_bib31","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2125.2011.04088.x","article-title":"Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study","volume":"73","author":"Mendzelevski","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.gtc.2025.02.007_bib32","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/gast.2001.21166","article-title":"Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder","volume":"120","author":"Bouras","year":"2001","journal-title":"Gastroenterology"},{"issue":"17","key":"10.1016\/j.gtc.2025.02.007_bib34","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1080\/14656566.2019.1668927","article-title":"An overview of the efficacy and safety of prucalopride for the treatment of chronic idiopathic constipation","volume":"20","author":"Daniali","year":"2019","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.gtc.2025.02.007_bib35","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/14656566.2015.996547","article-title":"Efficacy and safety of prucalopride in adults and children with chronic constipation","volume":"16","author":"Diederen","year":"2015","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"10.1016\/j.gtc.2025.02.007_bib36","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1053\/j.gastro.2014.09.005","article-title":"Prucalopride is no more effective than placebo for children with functional constipation","volume":"147","author":"Mugie","year":"2014","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.gtc.2025.02.007_bib37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40272-023-00612-8","article-title":"Safety and effectiveness of prucalopride in children with functional constipation with and without upper symptoms","volume":"26","author":"Velez","year":"2024","journal-title":"Paediatr Drugs"},{"issue":"11","key":"10.1016\/j.gtc.2025.02.007_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2016.58","article-title":"Effects of prucalopride on esophageal secondary peristalsis in humans","volume":"7","author":"Yi","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"issue":"1","key":"10.1016\/j.gtc.2025.02.007_bib39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40272-021-00489-5","article-title":"Prucalopride for treatment of upper gastrointestinal symptoms in children","volume":"24","author":"Hirsch","year":"2022","journal-title":"Paediatr Drugs"},{"issue":"21","key":"10.1016\/j.gtc.2025.02.007_bib40","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1212\/WNL.0000000000000458","article-title":"Acute refractory intestinal pseudo-obstruction in MELAS: efficacy of prucalopride","volume":"82","author":"Primiano","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.gtc.2025.02.007_bib41","first-page":"429","article-title":"Prucalopride in intestinal pseudo obstruction, paediatric experience and systematic review","volume":"84","author":"Mutalib","year":"2021","journal-title":"Acta Gastroenterol Belg"},{"issue":"8","key":"10.1016\/j.gtc.2025.02.007_bib42","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.14309\/ajg.0000000000000304","article-title":"Prucalopride in gastroparesis: a randomized placebo-controlled crossover study","volume":"114","author":"Carbone","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.gtc.2025.02.007_bib43","first-page":"e98","article-title":"A case report of prucalopride treatment in pediatric gastroparesis: a novel therapy","volume":"120","author":"Escobar-Serna","year":"2022","journal-title":"Arch Argent Pediatr"},{"key":"10.1016\/j.gtc.2025.02.007_bib44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/CEG.S384251","article-title":"Tenapanor in the treatment of irritable bowel syndrome with constipation: discovery, efficacy, and role in management","volume":"16","author":"Herekar","year":"2023","journal-title":"Clin Exp Gastroenterol"},{"issue":"5","key":"10.1016\/j.gtc.2025.02.007_bib45","doi-asserted-by":"crossref","first-page":"G543","DOI":"10.1152\/ajpgi.00233.2023","article-title":"NHE3 inhibitor tenapanor maintains intestinal barrier function, decreases visceral hypersensitivity, and attenuates TRPV1 signaling in colonic sensory neurons","volume":"326","author":"King","year":"2024","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"10.1016\/j.gtc.2025.02.007_bib46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.jrn.2024.07.003","article-title":"Tenapanor: a phosphate absorption inhibitor for the management of hyperphosphatemia in patients with kidney failure","volume":"35","author":"Hill","year":"2025","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.gtc.2025.02.007_bib47","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2147\/JPR.S243435","article-title":"Naldemedine: a new option for OIBD","volume":"13","author":"Coluzzi","year":"2020","journal-title":"J Pain Res"},{"issue":"10","key":"10.1016\/j.gtc.2025.02.007_bib48","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1089\/jpm.2024.0018","article-title":"Efficacy and safety of naldemedine for opioid-induced constipation in children","volume":"27","author":"Miura","year":"2024","journal-title":"J Palliat Med"},{"issue":"1","key":"10.1016\/j.gtc.2025.02.007_bib49","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12325-019-01116-z","article-title":"Current US Food and Drug Administration-approved pharmacologic therapies for the treatment of irritable bowel syndrome with diarrhea","volume":"37","author":"Brenner","year":"2020","journal-title":"Adv Ther"},{"issue":"7","key":"10.1016\/j.gtc.2025.02.007_bib50","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s00431-022-04459-y","article-title":"A therapeutic guide on pediatric irritable bowel syndrome and functional abdominal pain-not otherwise specified","volume":"181","author":"Rexwinkel","year":"2022","journal-title":"Eur J Pediatr"},{"issue":"1\u20133","key":"10.1016\/j.gtc.2025.02.007_bib51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.regpep.2009.03.012","article-title":"Opioid receptors in the gastrointestinal tract","volume":"155","author":"Holzer","year":"2009","journal-title":"Regul Pept"},{"key":"10.1016\/j.gtc.2025.02.007_bib52","series-title":"StatPearls [Internet]","article-title":"Loperamide. 2024","author":"Sahi","year":"2025"},{"issue":"3","key":"10.1016\/j.gtc.2025.02.007_bib53","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa1505180","article-title":"Eluxadoline for irritable bowel syndrome with diarrhea","volume":"374","author":"Lembo","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.gtc.2025.02.007_bib54","first-page":"438","article-title":"Eluxadoline (Viberzi): a mu-opioid receptor agonist for the treatment of irritable bowel syndrome with diarrhea","volume":"42","author":"Maltz","year":"2017","journal-title":"P T"},{"issue":"4","key":"10.1016\/j.gtc.2025.02.007_bib55","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/17474124.2017.1298442","article-title":"New therapeutic options for IBS: the role of the first in class mixed micro- opioid receptor agonist and delta-opioid receptor antagonist (mudelta) eluxadoline","volume":"11","author":"Corsetti","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2025.02.007_bib56","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2147\/DDDT.S216056","article-title":"Update on eluxadoline for the treatment of irritable bowel syndrome with diarrhea: patient selection and perspectives","volume":"14","author":"Liu","year":"2020","journal-title":"Drug Des Dev Ther"},{"issue":"3","key":"10.1016\/j.gtc.2025.02.007_bib57","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.cgh.2017.08.006","article-title":"Risk of pancreatitis following treatment of irritable bowel syndrome with eluxadoline","volume":"16","author":"Gawron","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.gtc.2025.02.007_bib58","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40272-015-0142-4","article-title":"Management of functional constipation in children: therapy in Practice","volume":"17","author":"Koppen","year":"2015","journal-title":"Paediatr Drugs"},{"issue":"6","key":"10.1016\/j.gtc.2025.02.007_bib59","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-042101","article-title":"Pharmacologic treatment in functional abdominal pain disorders in children: a systematic review","volume":"147","author":"Rexwinkel","year":"2021","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.gtc.2025.02.007_bib60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2217\/17455057.3.1.15","article-title":"Alosetron: an effective treatment for diarrhea-predominant irritable bowel syndrome","volume":"3","author":"Harris","year":"2007","journal-title":"Womens Health (Lond)"},{"issue":"11","key":"10.1016\/j.gtc.2025.02.007_bib61","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/apt.17426","article-title":"Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: the TRITON trial","volume":"57","author":"Gunn","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.gtc.2025.02.007_bib62","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12876-017-0734-2","article-title":"Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Qi","year":"2018","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"10.1016\/j.gtc.2025.02.007_bib63","doi-asserted-by":"crossref","first-page":"196","DOI":"10.5009\/gnl16126","article-title":"Small intestinal bacterial overgrowth and irritable bowel syndrome: a bridge between functional organic dichotomy","volume":"11","author":"Ghoshal","year":"2017","journal-title":"Gut Liver"},{"key":"10.1016\/j.gtc.2025.02.007_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101154","article-title":"Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: a systematic review and meta-analysis","volume":"41","author":"McFarland","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.gtc.2025.02.007_bib65","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.clnesp.2024.02.025","article-title":"Efficacy and safety of probiotics in irritable bowel syndrome: a systematic review and meta-analysis","volume":"60","author":"Yang","year":"2024","journal-title":"Clin Nutr ESPEN"},{"issue":"7","key":"10.1016\/j.gtc.2025.02.007_bib66","first-page":"455","article-title":"Antibiotics for the treatment of irritable bowel syndrome","volume":"7","author":"Basseri","year":"2011","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2025.02.007_bib67","series-title":"StatPearls [Internet]","article-title":"Rifaximin. 2023","author":"Robertson","year":"2025"},{"issue":"7","key":"10.1016\/j.gtc.2025.02.007_bib68","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/17425255.2018.1488964","article-title":"Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome","volume":"14","author":"Bruzzese","year":"2018","journal-title":"Expet Opin Drug Metabol Toxicol"},{"issue":"Suppl 1","key":"10.1016\/j.gtc.2025.02.007_bib69","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000081990","article-title":"Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential","volume":"51","author":"Scarpignato","year":"2005","journal-title":"Chemotherapy"},{"issue":"10","key":"10.1016\/j.gtc.2025.02.007_bib70","first-page":"1314","article-title":"Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome","volume":"17","author":"Scarpellini","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.gtc.2025.02.007_bib71","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/MPG.0b013e3181effa3b","article-title":"Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain","volume":"52","author":"Collins","year":"2011","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gtc.2025.02.007_bib72","article-title":"The gut-brain axis and pain signalling mechanisms in the gastrointestinal tract","author":"Meerschaert","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.gtc.2025.02.007_bib73","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jamapediatrics.2021.5750","article-title":"Effect of open-label placebo on children and adolescents with functional abdominal pain or irritable bowel syndrome: a randomized clinical trial","volume":"176","author":"Nurko","year":"2022","journal-title":"JAMA Pediatr"},{"issue":"2","key":"10.1016\/j.gtc.2025.02.007_bib74","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.neurom.2023.07.005","article-title":"Percutaneous electrical nerve field stimulation in children and adolescents with functional dyspepsia-integrating a behavioral intervention","volume":"27","author":"Santucci","year":"2024","journal-title":"Neuromodulation"},{"issue":"3","key":"10.1016\/j.gtc.2025.02.007_bib75","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S2468-1253(19)30256-0","article-title":"New advances in the treatment of paediatric functional abdominal pain disorders","volume":"5","author":"Santucci","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.gtc.2025.02.007_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/children3010005","article-title":"Functional nausea in children: a review of the literature and need for diagnostic criteria","volume":"3","author":"Russell","year":"2016","journal-title":"Children"},{"issue":"4","key":"10.1016\/j.gtc.2025.02.007_bib77","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1053\/j.gastro.2009.06.060","article-title":"Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders","volume":"137","author":"Saps","year":"2009","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.gtc.2025.02.007_bib78","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/MPG.0000000000001416","article-title":"Treatment of functional abdominal pain with antidepressants: benefits, adverse effects, and the gastroenterologist\u2019s role","volume":"65","author":"Zar-Kessler","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"10.1016\/j.gtc.2025.02.007_bib79","article-title":"Antidepressants for functional abdominal pain disorders in children and adolescents","volume":"2","author":"de Bruijn","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.gtc.2025.02.007_bib80","doi-asserted-by":"crossref","first-page":"756","DOI":"10.14309\/ajg.0000000000000589","article-title":"Comparison of the efficacy of buspirone and placebo in childhood functional abdominal pain: a randomized clinical trial","volume":"115","author":"Badihian","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.gtc.2025.02.007_bib81","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.cgh.2012.06.036","article-title":"Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia","volume":"10","author":"Tack","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.gtc.2025.02.007_bib82","article-title":"Safety, pharmacokinetics, and efficacy of olorinab, a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, in a phase 2a study of patients with chronic abdominal pain associated with crohn\u2019s disease","volume":"3","author":"Yacyshyn","year":"2021","journal-title":"Crohns Colitis 360"},{"issue":"7","key":"10.1016\/j.gtc.2025.02.007_bib83","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","article-title":"An introduction to the endogenous cannabinoid system","volume":"79","author":"Lu","year":"2016","journal-title":"Biol Psychiatry"},{"issue":"5","key":"10.1016\/j.gtc.2025.02.007_bib84","article-title":"Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: results from a phase 2b randomized placebo-controlled trial (CAPTIVATE)","volume":"35","author":"Chang","year":"2023","journal-title":"Neuro Gastroenterol Motil"},{"key":"10.1016\/j.gtc.2025.02.007_bib85","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jpeds.2015.10.052","article-title":"High prevalence of nausea among school children in Latin America","volume":"169","author":"Saps","year":"2016","journal-title":"J Pediatr"},{"key":"10.1016\/j.gtc.2025.02.007_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.583425","article-title":"Cyclic vomiting syndrome in children","volume":"11","author":"Raucci","year":"2020","journal-title":"Front Neurol"},{"issue":"4","key":"10.1016\/j.gtc.2025.02.007_bib87","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1037\/cpp0000508","article-title":"Innovations in the psychological care of pediatric disorders of gut\u2013brain interaction","volume":"11","author":"Essner","year":"2023","journal-title":"Clinical Practice in Pediatric Psychology"},{"key":"10.1016\/j.gtc.2025.02.007_bib88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fped.2022.848659","article-title":"Functional nausea is real and makes you sick","volume":"10","author":"Di Lorenzo","year":"2022","journal-title":"Front Pediat"},{"issue":"3","key":"10.1016\/j.gtc.2025.02.007_bib89","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/MPG.0000000000003876","article-title":"Percutaneous electrical nerve field stimulation for drug-refractory pediatric cyclic vomiting syndrome","volume":"77","author":"Karrento","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"10.1016\/j.gtc.2025.02.007_bib90","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5863\/1551-6776-27.1.12","article-title":"Cyclic vomiting syndrome in pediatric patients: a review of therapeutics","volume":"27","author":"Tillman","year":"2022","journal-title":"J Pediatr Pharmacol Therapeut"},{"author":"Ritchie","key":"10.1016\/j.gtc.2025.02.007_bib91"},{"issue":"11","key":"10.1016\/j.gtc.2025.02.007_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/ph14111089","article-title":"In vitro evaluation of a solid supersaturated self nanoemulsifying drug delivery system (Super-SNEDDS) of aprepitant for enhanced solubility","volume":"14","author":"Nazli","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.gtc.2025.02.007_bib94","series-title":"StatPearls [Internet]","article-title":"Antiemetic Neurokinin-1 Receptor Blockers. 2024","author":"Ibrahim","year":"2025"},{"issue":"3","key":"10.1016\/j.gtc.2025.02.007_bib95","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/j.jpainsymman.2021.02.007","article-title":"Long-term daily administration of aprepitant for the management of intractable nausea and vomiting in children with life-limiting conditions: a case series","volume":"62","author":"Patel","year":"2021","journal-title":"J Pain Symptom Manag"},{"issue":"10","key":"10.1016\/j.gtc.2025.02.007_bib96","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/s41409-018-0231-4","article-title":"Long-term aprepitant for nausea and vomiting associated with gastroparesis in hematopoietic stem cell transplantation","volume":"53","author":"Jacobse","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.gtc.2025.02.007_bib97","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/apt.12822","article-title":"Efficacy of the neurokinin-1 receptor antagonist aprepitant in children with cyclical vomiting syndrome","volume":"40","author":"Cristofori","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.gtc.2025.02.007_bib98","article-title":"Efficacy of aprepitant as a prophylactic medication in adults with cyclic vomiting syndrome","volume":"35","author":"Patel","year":"2023","journal-title":"Neuro Gastroenterol Motil"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855325000123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855325000123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T23:02:42Z","timestamp":1754002962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855325000123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":96,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0889855325000123"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2025.02.007","relation":{},"ISSN":["0889-8553"],"issn-type":[{"type":"print","value":"0889-8553"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Pharmacologic Treatments in Pediatric Neurogastroenterology","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gtc.2025.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}